<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293670</url>
  </required_header>
  <id_info>
    <org_study_id>9393FN/0001</org_study_id>
    <nct_id>NCT00293670</nct_id>
  </id_info>
  <brief_title>FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer</brief_title>
  <official_title>Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Finnish Prostate Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tampere</source>
  <brief_summary>
    <textblock>
      To compare intermittent androgen deprivation (LHRHa treatment) with continuous androgen
      deprivation (LHRHa treatment or orchidectomy)
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 1997</start_date>
  <completion_date>April 2015</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time To Progression (TTP)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall and prostate cancer-specific survival, time to treatment failure, quality of life</measure>
  </secondary_outcome>
  <enrollment>573</enrollment>
  <condition>Patients With T1-4 Advanced Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Goserelin (Zoladex)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        • Inclusion Criteria (run-in period): T1-T4, metastatic (M1) prostate cancer T1-T4,
        non-metastatic (M0) prostate cancer with PSA &gt; 60 ng/mL T3-T4, non-metastatic (M0) prostate
        cancer with PSA &gt; 20ng/mL T1-T4, N+ prostate cancer WHO performance status 0-2 Written
        informed consent

        • Inclusion criteria to the randomised period: Patients who fulfilled all entry criteria of
        the run-in period Patients who completed the 24-week run-in period Patients who responded
        to the 24-week run-in period with a decrease of PSA to &lt; 10 ng/mL. If the baseline was &lt;
        20ng/mL, at least 50% decrease from the baseline measurement is required

        Exclusion Criteria (run-in period):

        Any previous or concurrent treatment of prostate cancer, except TURP, 5-alpha reductase
        inhibitor, radical prostatectomy or radiotherapy Any medication/treatment affecting sex
        hormone status
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teuvo L Tammela, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere University Central Hospital, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TUCH (Tampere University Central Hospital)</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2006</study_first_submitted>
  <study_first_submitted_qc>February 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2006</study_first_posted>
  <last_update_submitted>February 16, 2006</last_update_submitted>
  <last_update_submitted_qc>February 16, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

